Treatment Selections using Risk-Benefit Profiles Based on Data from Comparative Randomized Clinical Trials with Multiple Endpoints: Supplementary Materials
نویسنده
چکیده
Treatment Selections using Risk-Benefit Profiles Based on Data from Comparative Randomized Clinical Trials with Multiple Endpoints: Supplementary Materials BRIAN CLAGGETT∗ Division of Cardiovascular Medicine, Harvard Medical School, Boston, Massachusetts, U.S.A. [email protected] LU TIAN Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, U.S.A. DAVIDE CASTAGNO Division of Cardiology, Department of Medical Sciences, University of Turin, Italy LEE-JEN WEI Department of Biostatistics, Harvard University, Boston, Massachusetts, U.S.A.
منابع مشابه
Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.
In a typical randomized clinical study to compare a new treatment with a control, oftentimes each study subject may experience any of several distinct outcomes during the study period, which collectively define the "risk-benefit" profile. To assess the effect of treatment, it is desirable to utilize the entirety of such outcome information. The times to these events, however, may not be observe...
متن کاملNumber Needed to Treat in Multiple Sclerosis Clinical Trials
Clinicians are expected to select a therapy based on their appraisal of evidence on benefit-to-risk profiles of therapies. In the management of relapsing-remitting multiple sclerosis (RRMS), evidence is typically expressed in terms of risk (proportion) of event, risk reduction, relative and hazard rate reduction, or relative reduction in the mean number of magnetic resonance imaging lesions. In...
متن کاملYou get what you measure: evaluating endpoints in MS clinical trials.
Neurology 2008;71:620–621 Since the emergence of the modern therapeutic era in multiple sclerosis (MS), the field has focused on identifying agents to prevent long-term disability progression. In lieu of measuring the true endpoint of interest, long-term disability progression, clinical trials typically measure surrogate endpoints, such as short-term disability progression or changes in lesion ...
متن کاملMultiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis.
BACKGROUND Myeloablative high-dose chemotherapy (HDT) followed by single autologous stem cell transplantation is currently the standard treatment for patients younger than 65 years with newly diagnosed multiple myeloma (MM). Several randomized controlled trials (RCTs) comparing HDT with standard dose therapy (SDT) have shown some benefit in overall survival (OS) and progression-free survival (P...
متن کاملThe Impact of a Web-based Family-oriented Supportive Education Program in Adherence to Treatment of The Heart Failure Patients after Discharge from Hospital; A Randomized Clinical Trial
Background and purpose: Patient adherence to treatment is considered as an important aspect of treatment. Inadequate adherence to treatment of the heart failure (HF) patients leads to intensification of the disease, high risk of re-hospitalization and death. In this respect, this study was designed and implemented with the aim to determine the effect of a Web-based family-oriented supportive ed...
متن کامل